Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 3518.

https://doi.org/10.1182/blood-2019-126509

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Phani Borra, MD, Cory Edward Mellon, MD

Blood (2019) 134 (Supplement_1): 4905.

https://doi.org/10.1182/blood-2019-128537

Published: 2019

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 2722.

https://doi.org/10.1182/blood-2018-99-115673

Published: 2018

Journal Articles

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Jorge E. Cortes, MD, Cristina Papayannidis, Catriona Jamieson, MD PhD, Gary J. Schiller, MD, Anna Candoni, MD, Brian Leber, MD, Claudia D. Baldus, MD, José A. Pérez-Simón, MD PhD, Weidong Wendy Ma, Corrado Gallo Stampino, Ashleigh O'Connell, Mirjana Zeremski, MD, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2018-99-110934

Published: 2018

Journal Articles

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Graham P. Collins, MD PhD, Rakesh Popat, Anastasios Stathis, Fatime Krasniqi, MD PhD, Toby A. Eyre, MD, Chin Hin Ng, MD, Dima El-Sharkawi, MD, Christian Schmidt, MD, Andreas Wicki, MDPhD, Elena Ivanova, PhD, Debora Schmitz, PhD, Sasa Dimitrijevic, PhD, Martin H. Dreyling, MD PhD

Blood (2016) 128 (22): 5893.

https://doi.org/10.1182/blood.V128.22.5893.5893

Published: 2016

Journal Articles

An Exploratory Study of the Effects of Strenuous Exercise On Markers of Activation of Coagulation, Inflammation and Endothelial Activation: Possible Implications for Exercise-Related Morbidity in Sickle Cell Trait

Micah J. Mooberry, MD, Robert Bradford, Robin Kellerman, RN, BSN, MSS, Eric Sobolewski, MS, Harry C. Stafford, MD, CAQSM, Robert G. McMurray, PhD, FACSM, Eric D. Ryan, PhD, Nigel S Key, MBChB

Blood (2012) 120 (21): 3224.

https://doi.org/10.1182/blood.V120.21.3224.3224

Published: 2012

Journal Articles

Consultation for Thrombocytopenia in Hospitalized Patients

Michael Boxer, MD

Blood (2012) 120 (21): 4659.

https://doi.org/10.1182/blood.V120.21.4659.4659

Published: 2012

Journal Articles

Delayed Recovery of Venous Oxygen Saturation and Lactate in SCT Subjects Following Exercise and Their Association with Red Cell Oxidative Stress

John C Wood, MD, Ph.D, Hongqiao Zhang, PhD, Adam M Bush, BS, Roberta Miyeko Kato, MD, Honglei Liu, PhD, Ani Dongelyan, BA, Anne Nord, RN, BSN, CCRP, Thomas D. Coates, MD, Henry J Forman, PhD

Blood (2012) 120 (21): 3244.

https://doi.org/10.1182/blood.V120.21.3244.3244

Published: 2012

Journal Articles

Abnormal Red Cell Deformability and Aggregation in Sickle Cell Trait

Jon Detterich, MD, Adam M Bush, BS, Roberta Miyeko Kato, MD, Rose Wenby, BS, Thomas D. Coates, MD, Herbert Meiselman, ScD, John C Wood, MD, Ph.D

Blood (2012) 120 (21): 1001.

https://doi.org/10.1182/blood.V120.21.1001.1001

Published: 2012

Journal Articles

Heme, Iron, and the Kidney

Karl A. Nath, MBChB

Blood (2010) 116 (21): SCI-26.

https://doi.org/10.1182/blood.V116.21.SCI-26.SCI-26

Published: 2010

Journal Articles

Prevention of Exercise-Related Death Unexplained by Preexisting Disease (EDU) Associated with Sickle Cell Trait (SCT) without Hemoglobin (Hb) Screening or Hb Specific Management

John A Kark, MD, Richard J. Labotka, MD, MS, John W Gardner, DM, DrPH, Frank T Ward, MD

Blood (2010) 116 (21): 945.

https://doi.org/10.1182/blood.V116.21.945.945

Published: 2010

Journal Articles

A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).

C Foster Matthew, MD, Chirag Amin, MD, Peter M Voorhees, MD, Hendrik W. Van Deventer, MD, Kristy L. Richards, PhD, MD, Anastasia Ivanova, Jennifer Whitman, RN, BSN, Thomas C. Shea, MD

Blood (2009) 114 (22): 2048.

https://doi.org/10.1182/blood.V114.22.2048.2048

Published: 2009

Journal Articles

Chronic Myeloid Leukemia in Pediatrics — First Results From Study CML-PAED II.

Meinolf Suttorp, MD, PhD, Christian Thiede, MD, PhD, Josefine T Tauer, BS, MS, Silja Roettgers, PhD, Petr Sedlacek, MD, PhD, Jochen Harbott, PhD

Blood (2009) 114 (22): 342.

https://doi.org/10.1182/blood.V114.22.342.342

Published: 2009

Journal Articles

Severe Rhabdomyolysis and Acute Renal Failure Secondary to Use of All–Trans-Retinoic Acid in a Patient with Acute Promyelocytic Leukemia.

Shenxian Qian, MD, Yaping Xie, Xilian Huang, DaQuan Gao, LiRong Liu, Kuang Chen

Blood (2009) 114 (22): 4138.

https://doi.org/10.1182/blood.V114.22.4138.4138

Published: 2009

Journal Articles

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

Dianna Howard, MD, Jane Liesveld, MD, Gordon L. Phillips, II, MD, Monica L. Guzman, PhD, Craig T. Jordan, PhD

Blood (2008) 112 (11): 2953.

https://doi.org/10.1182/blood.V112.11.2953.2953

Published: 2008

Journal Articles

Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells

David Teachey, MD, Cecilia Sheen, Alix Eden Seif, MD, MPH, Valerie I. Brown, MD, PhD, Stephan A. Grupp, MD, PhD

Blood (2008) 112 (11): 2927.

https://doi.org/10.1182/blood.V112.11.2927.2927

Published: 2008

Journal Articles

Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Yoav H. Messinger, MD, Paul S. Gaynon, MD, Elizabeth Raetz, MD, Raymond Hutchinson, MD, MS, Steven DuBois, MD, Julia Glade Bender, MD, Richard Sposto, PhD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Bruce C. Bostrom, MD

Blood (2008) 112 (11): 1919.

https://doi.org/10.1182/blood.V112.11.1919.1919

Published: 2008

Journal Articles

HyperCKemia in CML Patients on Imatinib Mesylate.

Joanne D. Hewitt, BScN, Deborah A. Rusnak, RN, Nanette Cox-Kennett, MN, Loree M. Larratt, MD, Robert Turner, MD

Blood (2007) 110 (11): 2965.

https://doi.org/10.1182/blood.V110.11.2965.2965

Published: 2007

NARROW

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

An Exploratory Study of the Effects of Strenuous Exercise On Markers of Activation of Coagulation, Inflammation and Endothelial Activation: Possible Implications for Exercise-Related Morbidity in Sickle Cell Trait

Consultation for Thrombocytopenia in Hospitalized Patients

Delayed Recovery of Venous Oxygen Saturation and Lactate in SCT Subjects Following Exercise and Their Association with Red Cell Oxidative Stress

Abnormal Red Cell Deformability and Aggregation in Sickle Cell Trait

Heme, Iron, and the Kidney

Prevention of Exercise-Related Death Unexplained by Preexisting Disease (EDU) Associated with Sickle Cell Trait (SCT) without Hemoglobin (Hb) Screening or Hb Specific Management

A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).

Chronic Myeloid Leukemia in Pediatrics — First Results From Study CML-PAED II.

Severe Rhabdomyolysis and Acute Renal Failure Secondary to Use of All–Trans-Retinoic Acid in a Patient with Acute Promyelocytic Leukemia.

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells

Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

HyperCKemia in CML Patients on Imatinib Mesylate.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only